Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors
申请人:DART NEUROSCIENCE (CAYMAN) LTD.
公开号:US10239882B2
公开(公告)日:2019-03-26
The invention provides a chemical entity of Formula (I): (I), wherein R1, R2, R3, and R4, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.
本发明提供了式(I)的化学实体:(I),其中 R1、R2、R3 和 R4 具有本文所述的任一值,以及包含这种化学实体的组合物;制造它们的方法;以及它们在多种方法中的用途,包括代谢和反应动力学研究;检测和成像技术;放射性治疗;调节和治疗由 PDE2 活性介导的疾病;治疗神经系统疾病、中枢神经系统疾病、痴呆症、神经退行性疾病和创伤依赖性功能丧失;治疗中风,包括中风康复期间的认知和运动障碍;促进神经保护和神经恢复;提高认知和运动训练的效率;以及治疗外周疾病,包括血液病、心血管病、肠胃病和皮肤病。